aml

LGN-523 (AML-01) is a humanized antibody expressed in CHO cells, targeting CD98. This antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.66 kDa. The isotype control for LGN-523 (AML-01) is HumanIgG1kappa, Isotype Control.

Bamlanivimab, an Anti-Human SARS-CoV-2 monoclonal antibody (mAb), was the first of its kind to receive Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in November 2020 for COVID-19 treatment. However, its authorization was withdrawn in April 2021 due to emerging SARS-CoV-2 variants resistant to the antibody [1].

Amlitelimab (KY1005) is a monoclonal antibody targeting OX40 ligand (OX40L), inhibiting KLH-driven immune responses, used in the study of atopic dermatitis.

Pamlectabart is a humanised antibody targeting TNFRSF17/BCMA, which can be used to synthesise the antibody-drug conjugate (ADC) Pamlectabart tismanitin for the study of multiple myeloma.

Amlenetug is a humanized IgG1κ antibody targeting SNCA, with its corresponding isotype control being HumanIgG1kappa, Isotype Control.

Ulocuplumab (BMS-936564) is a fully human anti-CXCR4 IgG4 antibody.Ulocplumab exhibits antitumor activity in acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), and multiple myeloma transplantation models.Ulocplumab inhibits the migration of chronic lymphocytic leukemia (CLL) cells under CXCR4 activation, induces apoptosis, and inhibits the growth and migration of cancer cells. Ulocplumab inhibits CXCL12-mediated chronic lymphocytic leukemia (CLL) cell migration in response to CXCR4 activation and induces apoptosis.)

Tepoditamab (MCLA-117) is a bispecific monoclonal antibody targeting CLEC12A on myeloid cells and CD3 on cytotoxic T cells. As a myeloid differentiation antigen, CLEC12A allows the compound to eliminate AML leukemia progenitor and stem cells through T cell-mediated proliferative lysis, making it valuable in acute myeloid leukemia (AML) research [1].

Talacotuzumab (JNJ 56022473) is an IgG1 fully humanized CD123 neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has a high affinity for CD123, CD32b/c, CD16-158F and CD16-158V, with KD of 0.43 nM, 188 nM, 46 nM and 16.8 nM, respectively. Talacotuzumab inhibits IL-3 signaling in target cells by inhibiting IL-3 binding to CD123. Talacotuzumab induces mutations in the Fc region to increase affinity for CD16 (FCγriiia), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab inhibits leukemia cell growth in xenografted mouse models of acute myeloid leukemia (AML).

Flotetuzumab (MGD006; S80880), an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule, reactivates T cells through concurrent engagement with CD123 on target cells and CD3 on effector T cells, facilitating T-cell-mediated cytotoxicity in target cells. Demonstrating an inhibitory effect in a mouse model of patient-derived xenograft (PDX) for acute myeloid leukemia (AML) [1] [2], Flotetuzumab offers potential therapeutic prospects for AML treatment.

Vadastuximab (Anti-Human CD33 Recombinant Antibody) is a humanized anti-CD33 monoclonal antibody that can be used for the synthesis of the ADC compound Vadastuximab talirine and for the study of acute myeloid leukemia (AML).

Vixtimotamab (AMV-564; TandAb T564), a bispecific tetravalent tandem diabody (TandAb), selectively targets human CD33 and CD3 antigens, and is used in acute myeloid leukemia (AML) research [1].

Lintuzumab (HuM-195) is a non-coupled humanized mouse monoclonal antibody directed against the cell-surface myelomonocyte differentiation antigen, CD33, with anti-leukemic activity that reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells.Lintuzumab has antitumor activity and induces cell death directly via CDC or ADCC. Lintuzumab has anti-tumor activity and induces cell death directly via CDC or ADCC.

Emerfetamab (AMG 673) is a dual-specificity T-cell engager (bispecific T-cell engager) with an extended half-life that targets both CD33 and CD3. By redirecting T cells towards CD33+ cells, Emerfetamab induces T-cell mediated cytotoxicity against progenitor cells in acute myeloid leukemia (AML).

Eluvixtamab (AMG-330) is a bispecific T-cell engager targeting CD33. It recognizes a linear epitope within the CD33 V-set domain, with a core sequence of IPYYDKN. By binding to CD33 on AML cells and CD3 on T cells, Eluvixtamab facilitates the destruction of CD33+ cells by T cells.

Emirodatamab (AMG-427) is an anti-FLT3/CD3 bispecific T-cell engager with an extended half-life. It can induce high cytotoxicity in primary AML progenitor cells and enhance FLT-3 expression. Combining Emirodatamab with anti-PD-1 antibodies increases T-cell dependent cytotoxicity (TDCC). This compound is under investigation for use in relapsed or refractory AML.

MGTA-117 is a humanized monoclonal antibody that targets CD117. It carries an amanitin payload and is used to synthesize antibody-drug conjugates (ADC). MGTA-117 demonstrates potent antitumor activity, enhancing survival in three acute myeloid leukemia (AML) xenograft models [Kasumi-1, AML PDX 1, and AML PDX 2]. It is applicable for AML, myelodysplastic syndromes with excess blasts (MDS-EB), and preconditioning for hematopoietic stem cell transplantation (HSCT) in gene therapy.

AT-1413 is a humanized monoclonal antibody (mAb) targeting CD43. It triggers antibody-dependent cell-mediated cytotoxicity (ADCC) in melanoma cell lines and acute myeloid leukemia (AML) cells. Additionally, AT-1413 shows antitumor activity in an AML mouse model. This compound is applicable for studies involving acute myeloid leukemia, breast cancer, malignant melanoma, and myelodysplastic syndrome. The recommended isotype control is HumanIgG1kappa, Isotype Control.

BI-836858 is a fully humanized IgG1 anti-CD33 monoclonal antibody. It is modified at the Fc fragment to enhance binding with FcγRIIIa (CD16). BI-836858 exhibits antibody-dependent cellular cytotoxicity (ADCC) activity and is utilized in research related to acute myeloid leukemia (AML).

RO-5429083 is a humanized monoclonal antibody inhibitor that targets CD44. It is used in research related to acute myeloid leukemia (AML) and solid tumors.

MEN1112 (OBT357NF) is a humanized monoclonal antibody that selectively targets Bst1/CD157, with an EC50 value of 1 nM. It demonstrates significant antitumor activity against acute myeloid leukemia (AML) cells and holds potential for research into hematologic malignancies, including AML.

CSL-360 is a chimeric non-conjugated IgG1 monoclonal antibody that targets CD123. It effectively inhibits the binding of IL-3 to CD123, thereby preventing IL-3-induced cell proliferation. CSL-360 is utilized in research related to acute myeloid leukemia (AML).

IGN523 is an anti-CD98 antibody (hCD98, KD = 0.55 nM) that induces antibody-dependent cell-mediated cytotoxicity (ADCC). It permeabilizes lysosomal membranes and inhibits essential amino acid transport function, leading to caspase-3 and caspase-7 mediated apoptosis of tumor cells. IGN523 inhibits tumor growth in various tumor xenograft models and can be used for research on cancers such as non-small cell lung cancer (NSCLC) and acute myeloid leukemia (AML).

LY-2624587 is a humanized IgG4 monoclonal antibody antagonist targeting CXCR4. It effectively blocks the interaction between SDF-1 and CXCR4, as well as SDF-1-induced GTP binding. LY-2624587 significantly inhibits cellular migration and induces apoptosis in human lymphoma and leukemia cells. Additionally, LY-2624587 suppresses cell signaling mediated by CXCR4 and SDF-1, including MAPK and AKT activation. This compound is utilized in research on human hematological malignancies, such as acute myeloid leukemia (AML).